Latest From Gritstone Oncology
Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Gritstone Oncology
- Senior Management
Andrew Allen, MD, PhD, Pres. & CEO
Jean-Marc Bellemin, EVP, CFO
Matthew Hawryluk, PhD, EVP, CBO
Karin Jooss , PhD, EVP, Research & CSO
Roman Yelensky, PhD, EVP, CTO
Raphael F Rousseau, MD, PhD, EVP, CMO
- Contact Info
Phone: (510) 871-6100
5858 Horton St.
Emeryville, CA 94608
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.